Natural advances in eczema care

Cutis

Volumn 80, Issue 6 SUPPL., 2007, Pages 2-16

  Eichenfield, Lawrence F ^a,b   Fowler Jr , Joseph F ^c   Rigel, Darrell S ^d   Taylor, Susan C ^e,f  

^a RADY CHILDREN'S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of Louisville School of Medicine   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^f Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE; FILAGGRIN; INTERMEDIATE FILAMENT PROTEIN; SUNSCREEN;

ARTICLE; ECZEMA; EPIDERMIS; GENETICS; HUMAN; MELANOMA; METABOLISM; MUTATION; PHYTOTHERAPY; SKIN PIGMENTATION; THERMOREGULATION;

CERAMIDES; ECZEMA; EPIDERMIS; HUMANS; INTERMEDIATE FILAMENT PROTEINS; MELANOMA; MUTATION; PHYTOTHERAPY; SKIN PIGMENTATION; SUNSCREENING AGENTS; WATER LOSS, INSENSIBLE;

EID: 38049054044     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. National Institute for Allergy and Infectious Disease. Significant items in House and Senate Appropriations Committee Reports. 2005. Available at: http: //www3.niaid.nih.gov/about/overview/pdf/fy06_reports.pdf. AccessedSeptember 25, 2007.
2. National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health. Atopic dermatitis (a type of eczema). Available at: http://www.niams.nih.gov/Health_Info/Atopic_Dermatitis / atopic_dermatitis_hoh.pdf. Accessed September 19, 2007.
3. Hanifin JM, Reed ML, Eczema Prevalence and Impact Working Group. A population-based survey of eczema prevalence in the United States. Dermatitis. 2007;18: 82-91.
4. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1980;92: 44-47.
5. Williams HC. On the definition and epidemiology of atopic dermatitis. Dermatol Clin. 1995;13: 649-657.
6. Eichenfield LF, Hanifin JM, Luger TA, et al. Consensus conference on pediatric atopic dermatitis. J Am Acad Dermatol. 2003;49:1088-1095.
7. Beattie PE, Lewis-Jones MS. A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases. Br J Dermatol 2006;155:145-151.
8. Absolon CM, Cottrell D, Eldridge SM, et al. Psychological disturbance in atopic eczema: the extent of the problem in school-aged children. Br J Dermatol. 1997;137: 241-245.
9. Leung DY, Boguniewicz M, Howell MD, et al. New insights into atopic dermatitis. J Clin Invest. 2004;113: 651-657.
10. Allam JP, Bieber T, Novak N. Recent highlights in the pathophysiology of atopic eczema. Int Arch Allergy Immunol. 2005;136:191-197. Epub February 8, 2005.
11. Leung D, Eichenfield L, Boguniewicz M. Atopic dermatitis. In: Wolff K, Goldsmith LA, Katz SI, et al, eds. Fitzpatrick's Dermatology in General Medicine. 7th ed. New York, NY: McGraw-Hill Professional; 2007: 1180-1193.
12. EczemaNet. The where, how and why of eczema. Available at: http://www.skincarephysicians.com/OLD/eczemanet_ old_2004/april.html. Accessed September 7, 2007.
13. Imokawa G. Lipid abnormalities in atopic dermatitis. J Am Acad Dermatol. 2001;45(suppl 1):S29-S32.
14. Cork M, Robinson D, Vasilopoulos Y, et al. New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions. J Allergy Clin Immunol. 2006;118:3-21. Epub June 9, 2006.
15. Seguchi T, Cui CY, Kusuda S, et al. Decreased expression of filaggrin in atopic skin. Arch Dermatol Res. 1996;288:442-446.
16. Weidinger S, Illig T, Baurecht H, et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations [published corrections appear in J Allergy Clin Immunol. 2006;118:724 and J Allergy Clin Immunol. 2006;118:922]. J Allergy Clin Immunol. 2006;118:214-219. Epub June 9, 2006.
17. Werner Y, Lindberg M. Transepidermal water loss in dry and clinically normal skin in patients with atopic dermatitis. Acta Derm Venereol. 1985;65: 102-105.
18. Imokawa G, Abe A, Jin K, et al. Decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin? J Invest Dermatol. 1991;96:523-526.
19. Di Nardo A, Wertz P, Giannetti A, et al. Ceramide and cholesterol composition of the skin of patients with atopic dermatitis. Acta Derm Venereol. 1998;78: 27-30.
20. Sator PG, Schmidt JB, Honigsmann H. Comparison of epidermal hydration and skin surface lipids in healthy individuals and in patients with atopic dermatitis. J Am Acad Dermatol. 2003;48:352-358.
21. Lebwohl M, Herrmann LG. Impaired skin barrier function in dermatologic disease and repair with moisturization. Cutis. 2005;76(suppl 6):7-12.
22. Loden M. The skin barrier and use of moisturizers in atopic dermatitis. Clin Dermatol. 2003;21:145-157.
23. Berger TG, Duvic M, Van Voorhees AS, et al. The use of topical calcineurin inhibitors in dermatology: safety concerns, report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol. 2006;54:818-823.
24. Halder RM, Grimes PE, McLaurin CI, et al. Incidence of common dermatoses in a predominantly black dermatologic practice. Cutis. 1983;32:388, 390.
25. Sanchez MR. Cutaneous diseases in Latinos. Dermatol Clin. 2003;21:689-697.
26. Stephens TJ, Oresajo C. Ethnic sensitive skin: a review. Cosmet Toiletries. 1994;109:75-80.
27. Stamatas GN, Kollias N. Blood stasis contributions to the perception of skin pigmentation. J Biomed Opt. 2004;9:315-322.
28. Taylor SC. Skin of color: biology, structure, function, and implications for dermatologic disease. J Am Acad Dermatol. 2002;46(suppl 2):S41-S62.
29. Grimes PE, Hunt SG. Considerations for cosmetic sur-gery in the black population. Clin Plast Surg. 1993;20: 27-34.
30. Food and Drug Administration, HHS. Skin protectant drug products for over-the-counter human use; final monograph, final rule. Fed Regist. 2003;68: 33362-33381.
31. Grais ML. Role of colloidal oatmeal in dermatologitreatment of the aged. AMA Arch Derm Syphilol. 1953;68: 402-407.
32. Wallo W, Nebus J, Nystrand G, et al. Agents with adjunctive therapeutic potential in atopic dermatitis. Poster presented at: 65th Annual Meeting of the American Academy of Dermatology; February 2-6, 2007; Washington, DC. P712.
33. Hart J, Polla C, Hull JC. Oat fractions. Cosmet Toiletries. 1998;113:45-52.
34. Data on file. Warhol J. Biological activity of oat compounds: a review of the scientific and medical literature. Skillman, NJ: Johnson & Johnson Consumer Companies; 2000.
35. Zhou M, Robards K, Glennie-Holmes M, et al. Oat lipids. J Am Oil Chem Soc. 1999;76:159-169.
36. Nebus J, Wallo W, Fowler J. Evaluating the safety and tolerance of a body wash and moisturizing regimen in patients with atopic dermatitis. Poster presented at: 65th Annual Meeting of the American Academy of Dermatology; February 2-6, 2007; Washington, DC. P714.
37. Data on file. Nebus J. Statistical report. Skillman, NJ: Johnson & Johnson Products Worldwide; 2006.
38. Smith G. Ashy skin. Skin of Color Scientific Council; June 27, 2004; Philadelphia, Pa.
39. Nebus J, Smith G, Miller D, et al. Alleviating dry, ashen skin in patients with skin of color. Poster presented at: 62nd Annual Meeting of the American Academy of Dermatology; February 6-11, 2004; Washington, DC. P294.
40. Schmaus G, Herrmann M, Joppe H, et al. Oat avenanthramides: new actives to reduce itch sensation in skin. Paper presented at: 23rd Congress of the International Federation of Societies of Cosmetic Chemists; October 24-27, 2004; Orlando, Fla.
41. Douglass J, Dhami D, Bulpitt M, et al. Intradermal challenge with interleukin-8 causes tissue oedema and neutrophil accumulation in atopic and non-atopic human subjects. Clin Exp Allergy. 1996;26:1371-1379.
42. Nakamura H, Aoki M, Tamai K, et al. Prevention and regression of atopic dermatitis by ointment containing NF-κB decoy oligodeoxynucleotides in NC/Nga atopic mouse model. Gene Ther. 2002;9: 1221-1229.
43. Liebel F, Southall M, Oddos T, et al. Topical formulation containing parthenolide-free extract of feverfew is highly effective in clinically reducing erythema induced by irritation or barrier disruption of the skin. Poster presented at: 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, La. P1047.
44. Nebus J, Wallo W, Smith G, et al. Evaluating topical preparations in sensitive skin patients. Poster presented at: 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, La. P1027.
45. Yokota T, Nishio H, Kubota Y, et al. The inhibitory effect of glabridin from licorice extracts on melanogenesis and inflammation. Pigment Cell Res. 1998;11:355-361.
46. Dieck K, Ceilley R, Immeyer J, et al. Anti-inflammatory properties of licochalcone A from Glycyrrhiza inflata on various human skin cells. Poster presented at: 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, La.
47. Chamlin SL, Kao J, Frieden IJ, et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol. 2002;47: 198-208.
48. Ebner F, Heller A, Rippke F, et al. Topical use of dexpanthenol in skin disorders. Am J Clin Dermatol. 2002;3: 427-433.
49. Ashida Y, Denda M. Dry environment increases mast cell number and histamine content in dermis in hairless mice. Br J Dermatol. 2003;149: 240-247.
50. Denda M, Sato J, Tsuchiya T, et al. Low humidity stimulates epidermal DNA synthesis and amplifies the hyperproliferative response to barrier disruption: implication for seasonal exacerbations of inflammatory dermatoses. J Invest Dermatol. 1998;111: 873-878.
51. Conti A, Rogers J, Verdejo P, et al. Seasonal influences on stratum comeum ceramide 1 fatty acids and the influence of topical essential fatty acids. Int J Cosmet Sci. 1996;18: 1-12.
52. Jiang SJ, Chen JY, Lu ZF, et al. Biophysical and morphological changes in the stratum corneum lipids induced by UVB irradiation. J Dermatol Sci. 2006;44: 29-36.
53. National Cancer Institute. Surveillance epidemiology and end results: melanoma of the skin. Available at: http: //seer.cancer.gov/statfacts/html/ melan.html. Accessed: September 9, 2007.
54. Ries LAG, Melbert D, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2004. Available from: National Cancer Institute, Bethesda, Md. Available at: http: //seer.cancer.gov/csr/1975_2004/. Accessed September 9, 2007.
55. Cockburn MG, Zadnick J, Deapen D. Developing epidemic of melanoma in the Hispanic population of California. Cancer. 2006;106:1162-1168.
56. Byrd KM, Wilson DC, Hoyler SS, et al. Advanced presentation of melanoma in African Americans. J Am Acad Dermatol. 2004;50:21-24.
57. Jancin B. Less skin ca with daily sunscreen use. Skin & Allergy News. 2007;38(7):1, 9.
58. van der Pols JC, Williams GM, Pandeya N, et al. Prolonged prevention of squamous cell carcinoma of the skin by regular sunscreen use. Cancer Epidemiol Biomarkers Prev. 2006;15:2546-2548. Epub November 28, 2006.
59. Centers for Disease Control and Prevention (CDC). Sunburn prevalence among adults - United States, 1999, 2003, and 2004. MMWR Morb Mortal Wkly Rep. 2007;56:524-528.
60. Hall HI, Rogers JD. Sun protection behaviors among African Americans. Ethn Dis. 1999;9:126-131.
61. Schauder S, Ippen H. Contact and photocontact sensitivity to sunscreens, review of a 15-year experience and of the literature. Contact Dermatitis. 1997;37:221-232.
62. Foley P, Nixon R, Marks R, et al. The frequency of reactions to sunscreens: results of a longitudinal population-based study on the regular use of sunscreens in Australia. Br J Dermatol. 1993;128:512-518.
63. Hughes TM, Stone NM. Benzophenone 4: an emerging allergen in cosmetics and toiletries? Contact Dermatitis. 2007;56:153-156.
64. Pinnell S. Cutaneous photodamage, oxidative stress, and topical antioxidant protection. J Am Acad Dermatol. 2003:48:1-19; quiz 20-22.
65. Wulf HC, Stender IM, Lock-Andersen J. Sunscreens used at the beach do not protect against erythema: a new definition of SPF is proposed. Photodermatol Photoimmunol Photomed. 1997;13:129-132.
66. Huncharek M, Kupelnick B. Use of topical sunscreens and the risk of malignant melanoma: a meta-analysis of 9067 patients from 11 case-control studies. Am J Public Health. 2002;92:1173-1177.
67. Stokes R, Diffey B. How well are sunscreen users protected? Photodermatol Photoimmunol Photomed. 1997;13: 186-188.
68. Faurschou A, Wulf HC. The relation between sun protection factor and amount of sunscreen applied in vivo. Br J Dermatol. 2007;156:716-719.
69. Grosick T, Tanner P. Efficacy as used, not as tested, is true measure of sunscreen performance. Poster presented at: 62nd Annual Meeting of the American Academy of Dermatology; February 6-11, 2004, Washington, DC. P121.
70. Data on file. Chu M. Skillman, NJ: Johnson & Johnson; 2006.
71. Bonda C, Steinberg DC. A new photostabilizer for full spectrum sunscreens. Cosmet Toiletries. 2000;115: 37-45.
72. Nebus J, Wallo W, Smith G, et al. Clinical improvements in skin tone and texture using a facial moisturizer with a combination of total soy and SPF 30 UVA/UVB protection. Poster presented at: 64th Annual Meeting of the American Academy of Dermatology; March 3-7, 2006; San Francisco, Calif. P1106.
73. Rigel D, Cole C. Protection at high altitude in extreme sun conditions: sunscreen effectiveness and reapplication need evaluation. Poster presented at: 64th Annual Meeting of the American Academy of Dermatology; March 3-7, 2006; San Francisco, Calif. P2625.
74. Paine C, Sharlow E, Liebel F, et al. An alternative approach to depigmentation by soybean extracts via inhibition of the PAR-2 pathway. J Invest Dermatol. 2001;116:587-595.
75. Elmets CA, Singh D, Tubesing K, et al. Cutaneous photoprotection from ultraviolet injury by green tea polyphenols. J Am Acad Dermatol. 2001;44: 425-432.
76. Katiyar S, Elmets CA, Katiyar SK. Green tea and skin cancer: photoimmunology, angiogenesis and DNA repair. J Nutr Biochem. 2007; 18:287-296. Epub October 17, 2006.
77. + T cells in tumors. Photochem Photobiol. 2005;81: 1174-1179.
78. Tierney N, Liebel F, Kurtz E, et al. Daily use of a topical formulation containing parthenolide-free extract of fever-few clinically reduces the appearance of erythema due to ultraviolet exposure. Poster presented at: 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005; New Orleans, La. P1020.